Understand melanoma treatment options: A clinical overview of current therapeutic strategies

Understanding the Clinical Framework for Melanoma

Melanoma, a serious form of skin cancer arising from pigment-producing melanocytes, requires a highly individualized approach to management 1. The therapeutic strategy is determined primarily by the disease stage, tumor thickness (Breslow depth), location, and the presence of specific genetic mutations 2. Because melanoma can spread to distant organs, comprehensive staging and diagnostic assessment are critical before beginning any intervention 3. Modern oncology relies on a multidisciplinary team to balance the necessity of removing cancerous cells with the preservation of healthy tissue and patient quality of life 4.

Surgical Interventions for Localized Melanoma

Surgery remains the foundational treatment for localized melanoma, particularly for early-stage disease where the goal is complete removal of the tumor 5. A wide local excision is the standard procedure, involving the removal of the melanoma along with a specific margin of healthy surrounding tissue to ensure clear edges 6. The width of these margins is dictated by the tumor depth and anatomical site 7. In cases where melanoma is in a highly sensitive area, such as the face, practitioners may utilize Mohs surgery or staged excision to minimize cosmetic impact while maintaining a high curative success rate 8.

The Role of Lymph Node Evaluation

When staging progresses to stage IB or higher, or when specific risk factors are identified, the status of nearby lymph nodes becomes a central concern 9. A sentinel lymph node biopsy is often performed to determine if the cancer has migrated beyond the primary site 10. This procedure provides diagnostic information that helps clinicians refine the disease stage and determine if systemic therapy is required 11. Notably, data indicates that approximately 80% of individuals who undergo this procedure do not show evidence of cancer in their lymph nodes, demonstrating the selective nature of this diagnostic tool 12.

Systemic Therapies: Immunotherapy and Targeted Agents

For advanced or metastatic melanoma, systemic therapies have evolved into a cornerstone of care 13. Immunotherapy works by activating the patient’s immune system to identify and neutralize malignant cells 14. Immune checkpoint inhibitors, such as those targeting PD-1 or CTLA-4, represent significant advancements in patient survival 15. Simultaneously, targeted therapy is employed for tumors harboring specific gene mutations, such as BRAF V600 16. BRAF and MEK inhibitors are frequently combined to block the pathways that facilitate tumor growth, offering a specialized alternative to traditional systemic options 17.

Adjuvant and Neoadjuvant Considerations

The application of systemic therapies is increasingly moving toward earlier stages of the disease 18. Adjuvant therapy, administered after surgery, is considered for patients with resected stage IIIA melanoma or higher to reduce the risk of recurrence 19. Similarly, neoadjuvant approaches involve systemic treatment prior to surgery to potentially shrink tumors and improve surgical outcomes 20. The selection of these therapies often depends on the results of genomic profiling and biomarker testing, which help identify patients most likely to benefit from specific drug regimens 21.

Surveillance and Long-term Management

Post-treatment care is a lifelong commitment for individuals diagnosed with melanoma due to the elevated risk of recurrence or the development of new primary melanomas 22. Surveillance protocols typically include full skin examinations conducted at least annually, alongside physical assessment of lymph node basins 23. Imaging and ongoing monitoring for immune-related side effects are also vital components of the care plan 24. Through consistent follow-up, clinicians can monitor for changes and address potential complications early, which remains a key objective in the ongoing management of this condition 25.

Sources

1. American Cancer Society: Treatment of Melanoma Skin Cancer by Stage
2. FP Essentials: Management of Cutaneous Melanoma
3. Fred Hutch Cancer Center: Melanoma Treatment Options
4. Columbia University: Melanoma Treatments
5. Merck Manual Professional Edition: Melanoma (Malignant Melanoma)
6. Mayo Clinic: Advances in Staging and Surgical Treatment of Melanoma
7. World Journal of Surgical Oncology: Advances in the treatment of cutaneous tumors
8. Cancers (Basel): Drug Therapy for Melanoma: Current Updates and Future Prospects
9. Medscape: Melanoma, Immunotherapy: SITC 2025 Guideline Summary
10. Merck Manual Consumer Version: Melanoma (Malignant Melanoma)